Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 7.47
GNMK's Cash to Debt is ranked higher than
59% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. GNMK: 7.47 )
Ranked among companies with meaningful Cash to Debt only.
GNMK' s 10-Year Cash to Debt Range
Min: 7.47  Med: 6426.38 Max: No Debt
Current: 7.47
Equity to Asset 0.78
GNMK's Equity to Asset is ranked higher than
70% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. GNMK: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
GNMK' s 10-Year Equity to Asset Range
Min: 0.67  Med: 0.84 Max: 0.92
Current: 0.78
0.67
0.92
F-Score: 3
Z-Score: 6.73
M-Score: -2.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -122.67
GNMK's Operating margin (%) is ranked lower than
80% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. GNMK: -122.67 )
Ranked among companies with meaningful Operating margin (%) only.
GNMK' s 10-Year Operating margin (%) Range
Min: -4488.56  Med: -476.40 Max: -106.95
Current: -122.67
-4488.56
-106.95
Net-margin (%) -120.01
GNMK's Net-margin (%) is ranked lower than
78% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. GNMK: -120.01 )
Ranked among companies with meaningful Net-margin (%) only.
GNMK' s 10-Year Net-margin (%) Range
Min: -4383.77  Med: -478.54 Max: -107.98
Current: -120.01
-4383.77
-107.98
ROE (%) -45.90
GNMK's ROE (%) is ranked lower than
76% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.14 vs. GNMK: -45.90 )
Ranked among companies with meaningful ROE (%) only.
GNMK' s 10-Year ROE (%) Range
Min: -158.05  Med: -71.75 Max: -40.63
Current: -45.9
-158.05
-40.63
ROA (%) -39.12
GNMK's ROA (%) is ranked lower than
74% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: -0.33 vs. GNMK: -39.12 )
Ranked among companies with meaningful ROA (%) only.
GNMK' s 10-Year ROA (%) Range
Min: -115.7  Med: -58.79 Max: -35.46
Current: -39.12
-115.7
-35.46
ROC (Joel Greenblatt) (%) -381.86
GNMK's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. GNMK: -381.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GNMK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2957.74  Med: -614.04 Max: -395.21
Current: -381.86
-2957.74
-395.21
Revenue Growth (3Y)(%) 35.10
GNMK's Revenue Growth (3Y)(%) is ranked higher than
95% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. GNMK: 35.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GNMK' s 10-Year Revenue Growth (3Y)(%) Range
Min: -22.3  Med: 39.65 Max: 52.5
Current: 35.1
-22.3
52.5
EBITDA Growth (3Y)(%) -13.80
GNMK's EBITDA Growth (3Y)(%) is ranked lower than
71% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. GNMK: -13.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GNMK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.4  Med: -31.70 Max: -13.8
Current: -13.8
-63.4
-13.8
EPS Growth (3Y)(%) -13.80
GNMK's EPS Growth (3Y)(%) is ranked lower than
66% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. GNMK: -13.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GNMK' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.8  Med: -31.40 Max: -13.8
Current: -13.8
-62.8
-13.8
» GNMK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

GNMK Guru Trades in

GNMK Guru Trades in

GNMK Guru Trades in

Q2 2013

GNMK Guru Trades in Q2 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GNMK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.16
GNMK's P/B is ranked lower than
72% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 3.13 vs. GNMK: 5.16 )
Ranked among companies with meaningful P/B only.
GNMK' s 10-Year P/B Range
Min: 1.61  Med: 4.32 Max: 10.43
Current: 5.16
1.61
10.43
P/S 11.08
GNMK's P/S is ranked lower than
82% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 3.19 vs. GNMK: 11.08 )
Ranked among companies with meaningful P/S only.
GNMK' s 10-Year P/S Range
Min: 9.44  Med: 15.34 Max: 24.96
Current: 11.08
9.44
24.96
Current Ratio 8.15
GNMK's Current Ratio is ranked higher than
89% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 2.69 vs. GNMK: 8.15 )
Ranked among companies with meaningful Current Ratio only.
GNMK' s 10-Year Current Ratio Range
Min: 3.19  Med: 6.84 Max: 14.02
Current: 8.15
3.19
14.02
Quick Ratio 7.93
GNMK's Quick Ratio is ranked higher than
90% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. GNMK: 7.93 )
Ranked among companies with meaningful Quick Ratio only.
GNMK' s 10-Year Quick Ratio Range
Min: 3.15  Med: 6.60 Max: 13.78
Current: 7.93
3.15
13.78
Days Inventory 47.56
GNMK's Days Inventory is ranked higher than
91% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 131.50 vs. GNMK: 47.56 )
Ranked among companies with meaningful Days Inventory only.
GNMK' s 10-Year Days Inventory Range
Min: 47.43  Med: 62.09 Max: 90.13
Current: 47.56
47.43
90.13
Days Sales Outstanding 49.47
GNMK's Days Sales Outstanding is ranked higher than
77% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.21 vs. GNMK: 49.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
GNMK' s 10-Year Days Sales Outstanding Range
Min: 38.08  Med: 62.17 Max: 96.52
Current: 49.47
38.08
96.52

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.49
GNMK's Price/Net Cash is ranked higher than
71% of the 105 Companies
in the Global Medical Devices industry.

( Industry Median: 14.32 vs. GNMK: 7.49 )
Ranked among companies with meaningful Price/Net Cash only.
GNMK' s 10-Year Price/Net Cash Range
Min: 1.98  Med: 4.96 Max: 13.27
Current: 7.49
1.98
13.27
Price/Net Current Asset Value 6.50
GNMK's Price/Net Current Asset Value is ranked higher than
53% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 6.82 vs. GNMK: 6.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GNMK' s 10-Year Price/Net Current Asset Value Range
Min: 1.82  Med: 4.65 Max: 9.94
Current: 6.5
1.82
9.94
Price/Tangible Book 5.37
GNMK's Price/Tangible Book is ranked lower than
55% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.53 vs. GNMK: 5.37 )
Ranked among companies with meaningful Price/Tangible Book only.
GNMK' s 10-Year Price/Tangible Book Range
Min: 1.64  Med: 4.25 Max: 8.34
Current: 5.37
1.64
8.34
Price/Median PS Value 0.73
GNMK's Price/Median PS Value is ranked higher than
82% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.13 vs. GNMK: 0.73 )
Ranked among companies with meaningful Price/Median PS Value only.
GNMK' s 10-Year Price/Median PS Value Range
Min: 0.63  Med: 0.98 Max: 1.52
Current: 0.73
0.63
1.52
Earnings Yield (Greenblatt) (%) -12.97
GNMK's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. GNMK: -12.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GNMK' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -13.2  Med: 0.00 Max: 0
Current: -12.97
-13.2
0

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:GNF.Germany,
GenMark Diagnostics Inc was incorporated in the State of Delaware in February 2010. The Company is a molecular diagnostics company developing and commercializing its proprietary eSensor detection technology. Its proprietary electrochemical technology enables fast, accurate and highly sensitive detection of up to 72 distinct biomarkers in a single sample. The Company's XT-8 System received 510(k) clearance from the Food and Drug Administration and is designed to support molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified nucleic acid sample, its XT-8 system produces clear results. The Company's XT-8 System supports up to 24 test cartridges, of which each could be run independently, resulting in a highly convenient and flexible workflow for its customers, which are hospitals and reference laboratories. It intends to expand the use of its XT-8 System and diagnostic tests to those reference laboratories and hospitals in the United States which perform a high volume of molecular diagnostic tests. The Company's XT-8 System is an automated molecular diagnostic system that enables reference laboratories and hospitals to perform fast, accurate and easy-to-use molecular diagnostic tests. The XT-8 System, which employs its proprietary electrochemical detection technology, consists of a compact bench-top workstation with an integrated touch screen computer and an analyzer into which the self-contained, disposable test cartridges are inserted. The Company's proprietary eSensor technology is based on the competitive DNA hybridization and electrochemical detection. The Company's test cartridges are self-contained devices specifically programmed and configured for a given diagnostic test. Each test cartridge includes a sample compartment and a plastic cover that forms a hybridization chamber. The Company's XT-8 instrument is a multiplex workstation that has a modular design consisting of a base module and up to three test cartridge-processing towers of eight cartridge slots each. It faces competition in the molecular diagnostic testing markets with testing products and systems developed by public and private companies such as Cepheid, Gen-Probe, Inc., Siemens, Hologic, Inc., Innogenetics, Inc, Luminex Corporation, Nanosphere, Inc., Qiagen NV, Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd., Idaho Technologies and Abbott Diagnostics, a division of Abbott Laboratories. The Company's diagnostic tests also face competition with the LDTs developed by national and regional reference laboratories and hospitals. The design, development, manufacture, testing and sale of its diagnostic products are subject to regulation by numerous governmental authorities, the FDA, and corresponding state and foreign regulatory agencies.
» More Articles for GNMK

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: XPL, GNMK Jul 02 2012 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 
Weekly CFO Buys Highlight: Bank Mutual Corp., Heelys Inc., GenMark Diagnostics Inc., Regeneration Te Sep 19 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 

More From Other Websites
5 Stocks Ready for Breakouts Jun 19 2015
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 01 2015
GenMark Diagnostics to Present at the William Blair 35th Annual Growth Stock Conference May 27 2015
10-Q for GenMark Diagnostics, Inc. May 07 2015
GenMark Diagnostics reports 1Q loss May 05 2015
GenMark Diagnostics reports 1Q loss May 05 2015
GenMark Diagnostics Reports Q1 Financial Results May 05 2015
GenMark Diagnostics Inc Earnings Call scheduled for 4:30 pm ET today May 05 2015
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition May 05 2015
GenMark Diagnostics Reports Q1 Financial Results May 05 2015
Q1 2015 GenMark Diagnostics Inc Earnings Release - After Market Close May 05 2015
GenMark Diagnostics to Present at Bank of America Merrill Lynch 2015 Health Care Conference Apr 29 2015
GenMark Diagnostics to Present at Bank of America Merrill Lynch 2015 Health Care Conference Apr 29 2015
GenMark Announces Positive Preliminary Q1 Financial Results and ePlex™ Update Apr 16 2015
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Apr 16 2015
GenMark Announces Positive Preliminary Q1 Financial Results and ePlex™ Update Apr 16 2015
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Apr 02 2015
GENMARK DIAGNOSTICS, INC. Financials Mar 03 2015
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Financial Statements and Exhibits Feb 25 2015
GenMark Diagnostics reports 4Q loss Feb 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK